Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Treatment Interruption of Natalizumab
2009-017490-38Phase 2Completed
- Sponsor
- Biogen
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Biogen. Primary endpoints: Natalizumab concentration, Immune function and 2 more. Started Feb 2010; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2009-017490-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017490-38.